Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-08T08:04:16.044Z Has data issue: false hasContentIssue false

28 - Forkhead box proteins: the tuning forks in cancer development and treatment

from Part 2.1 - Molecular pathways underlying carcinogenesis: signal transduction

Published online by Cambridge University Press:  05 February 2015

Eric W.-F. Lam
Affiliation:
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK
Kyle W. Muir
Affiliation:
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK
Chuay-Yeng Koo
Affiliation:
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK
Edward P. Gelmann
Affiliation:
Columbia University, New York
Charles L. Sawyers
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Frank J. Rauscher, III
Affiliation:
The Wistar Institute Cancer Centre, Philadelphia
Get access

Summary

Introduction

Forkhead box (Fox) proteins belong to a superfamily of transcription factors that is characterized by a highly conserved “winged-helix” DNA-binding domain. Following the discovery of the first Fox transcription factor, FoxA, in Drosophila melanogaster, the identification of Fox genes has hitherto revealed at least 19 subclasses in humans (1). Fox proteins hold tight reins on determining cell fate, in particular cell proliferation, differentiation, and survival; thus it is predictable that the deregulation of these proteins has a major impact in the pathogenesis of cancer. Of the Fox proteins, the subfamilies FoxO, FoxM, FoxP, FoxC, and FoxA have been shown to participate in oncogenesis (2). As these Fox proteins recognize similar promoter elements on genomic DNA, they can potentially regulate the expression of overlapping gene targets. However, this chapter will focus on the involvement of the FoxO and FoxM1 proteins in cancer as there is an increasingly well-established and strong relationship between these two groups of Fox proteins through early tumorigenesis to advanced cancer progression and even chemotherapy response.

An overview of FoxO and FoxM1

The mammalian FoxO proteins, FoxO1, FoxO3a, FoxO4, and FoxO6, are downstream effectors of the PI3K-Akt (also called PKB) signaling pathway, a signaling cascade that is a focal point for deregulation in most cancers (3). The subcellular localization of FoxO, with the exception of the constitutively nuclear FoxO6, is typically dependent on the phosphorylation of these FoxO proteins by several key kinases, namely Akt/PKB, serum glucocorticord-induced protein kinase (SGK), CK1, IκB kinase (IKKβ), C-Jun N-terminal kinase (JNK), and p38 MAPK (4,5). It is well established that Akt-mediated phosphorylation of FoxO proteins results in cytoplasmic relocation and the consequent inability of these proteins to initiate transcription. Upon translocation to the nucleus, activated FoxO proteins are able to control cell fate by transcriptionally activating or repressing target genes by binding to the DNA of consensus sequences, and by interacting with other transcriptional co-activators such as p300/CREB-binding protein (CBP).

Type
Chapter
Information
Molecular Oncology
Causes of Cancer and Targets for Treatment
, pp. 328 - 335
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Weigel, D, Jurgens, G, Kuttner, F, Seifert, E, Jackle, H. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell 1989;57:645–58.CrossRef
Myatt, SS, Lam, EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nature Reviews Cancer 2007;7:847–59.CrossRef
Tzivion, G, Hay, N. PI3K-Akt-FoxO axis in cancer and aging. Biochimica et Biophysica Acta 2011;1813:1925.CrossRef
Ho, KK, Myatt, SS, Lam, EW. Many forks in the path: cycling with FoxO. Oncogene 2008;27:2300–11.CrossRef
Ho, KK, McGuire, VA, Koo, CY, et al. Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. Journal of Biological Chemistry 2012;287:1545–55.CrossRefGoogle ScholarPubMed
Koo, CY, Muir, KW, Lam, EW. FOXM1: from cancer initiation to progression and treatment. Biochimica et Biophysica Acta 2012;1819:28–37.CrossRef
Delpuech, O, Griffiths, B, East, P, et al. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Molecular and Cellular Biology 2007;27:4917–30.CrossRef
McGovern, UB, Francis, RE, Peck, B, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular Cancer Therapeutics 2009;8:582–91.CrossRef
Paik, JH, Kollipara, R, Chu, G, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007;128:309–23.CrossRef
Dong, XY, Chen, C, Sun, X, et al. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Research. 2006;66:6998–7006.CrossRef
Okabe, H, Satoh, S, Kato, T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Research 2001;61:2129–37.
Pilarsky, C, Wenzig, M, Specht, T, Saeger, HD, Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004;6:744–50.CrossRef
Ahmed, M, Uddin, S, Hussain, AR, et al. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2012;97:E1–E13.CrossRefGoogle ScholarPubMed
Dijkers, PF, Medema, RH, Pals, C, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Molecular and Cellular Biology 2000;20:9138–48.CrossRef
Medema, RH, Kops, GJ, Bos, JL, Burgering, BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000;404:782–7.CrossRef
Fernandez de, Mattos S, Essafi, A, Soeiro, I, et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Molecular and Cellular Biology 2004;24:10 058–71.
Schmidt, M, Fernandez de, Mattos S, van der Horst, A, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Molecular and Cellular Biology 2002;22:7842–52.CrossRef
Furukawa-Hibi, Y, Yoshida-Araki, K, Ohta, T, Ikeda, K, Motoyama, N. FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. Journal of Biological Chemistry 2002;277:26 729–32.CrossRefGoogle Scholar
Tran, H, Brunet, A, Grenier, JM, et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002;296:530–4.CrossRef
Wang, IC, Chen, YJ, Hughes, D, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Molecular and Cellular Biology 2005;25:10 875–94.
Laoukili, J, Kooistra, MR, Bras, A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nature Cell Biology 2005;7:126–36.CrossRef
Wonsey, DR, Follettie, MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Research 2005;65:5181–9.CrossRef
Gemenetzidis, E, Elena-Costea, D, Parkinson, EK, et al. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Research 2010;70:9515–26.CrossRef
Ahmad, A, Wang, Z, Kong, D, et al. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Research and Treatment 2010;122:337–46.CrossRef
Xie, Z, Tan, G, Ding, M, et al. Foxm1 transcription factor is required for maintenance of pluripotency of P19 embryonal carcinoma cells. Nucleic Acids Research 2010;38:8027–38.CrossRef
Zeng, J, Wang, L, Li, Q, et al. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. Journal of Pathology 2009;218:419–27.CrossRefGoogle ScholarPubMed
Li, SK, Smith, DK, Leung, WY, et al. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. Journal of Biological Chemistry 2008;283:16 545–53.CrossRefGoogle ScholarPubMed
Balli, D, Zhang, Y, Snyder, J, Kalinichenko, VV, Kalin, TV. Endothelial cell-specific deletion of transcription factor FoxM1 increases urethane-induced lung carcinogenesis. Cancer Research 2011;71:40–50.CrossRef
Kim, IM, Ackerson, T, Ramakrishna, S, et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Research 2006;66:2153–61.CrossRef
Yoshida, Y, Wang, IC, Yoder, HM, Davidson, NO, Costa, RH. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology. 2007;132:1420–31.CrossRef
Wang, Z, Banerjee, S, Kong, D, Li, Y, Sarkar, FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Research 2007;67:8293–300.CrossRef
Zhang, Y, Zhang, N, Dai, B, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Research 2008;68:8733–42.CrossRef
Park, HJ, Gusarova, G, Wang, Z, et al. Deregulation of FoxM1b leads to tumour metastasis. EMBO Molecular Medicine 2011;3:21–34.CrossRef
Overall, CM, Dean, RA. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Reviews 2006;25:69–75.CrossRef
van Kempen, LC, Coussens, LM. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002;2:251–2.CrossRef
Dai, B, Kang, SH, Gong, W, et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 2007;26:6212–19.CrossRef
Anderson, CD, Wang, J, Kumar, GN, et al. Dexamethasone induction of taxol metabolism in the rat. Drug Metabolism and Disposition 1995;23:1286–90.
Sunters, A, Fernandez de, Mattos S, Stahl, M, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. Journal of Biological Chemistry 2003;278:49 795–805.CrossRefGoogle ScholarPubMed
Sunters, A, Madureira, PA, Pomeranz, KM, et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Research 2006;66:212–20.CrossRef
Carr, JR, Park, HJ, Wang, Z, Kiefer, MM, Raychaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Research 2010;70:5054–63.CrossRef
Petsko, GA. Cancer chemotherapy: heavy metal revival. Nature 1995;377:580–1.CrossRef
Fernandez de, Mattos S, Villalonga, P, Clardy, J, Lam, EW. FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. Molecular Cancer Therapeutics 2008;7:3237–46.CrossRef
Shiota, M, Yokomizo, A, Kashiwagi, E, et al. Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin. Cancer Science 2010;101:1177–85.CrossRef
Kwok, JM, Peck, B, Monteiro, LJ, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Molecular Cancer Research 2010;8:24–34.CrossRef
Nitiss, JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews Cancer 2009;9:338–50.CrossRef
Hui, RC, Francis RE, Guest SK, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Molecular Cancer Therapeutics 2008;7:670–8.CrossRef
Hui, RC, Gomes, AR, Constantinidou, D, et al. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Molecular and Cellular Biology 2008;28:5886–98.CrossRef
Chen, J, Gomes, AR, Monteiro, LJ, et al. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One 2010;5:e12293.
Millour, J, de Olano, N, Horimoto, Y, et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Molecular Cancer Therapeutics 2011;10:1046–58.CrossRef
Bektas, N, Haaf, A, Veeck, J, et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008;8:42.CrossRef
Francis, RE, Myatt, SS, Krol, J, et al. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. International Journal of Oncology 2009;35:57–68.Google ScholarPubMed
Karadedou, CT, Gomes, AR, Chen, J, et al. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene 2011;31:1845–58.CrossRef
Zou, Y, Tsai, WB, Cheng, CJ, et al. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Research 2008;10:R21.
Madureira, PA, Varshochi, R, Constantinidou, D, et al. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. Journal of Biological Chemistry 2006;281:25 167–76.CrossRefGoogle ScholarPubMed
Millour, J, Constantinidou, D, Stavropoulou, AV, et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010;29:2983–95.CrossRef
Horimoto, Y, Hartman, J, Millour, J, et al. ERbeta1 represses FOXM1 expression through targeting ERalpha to control cell proliferation in breast cancer. American Journal of Pathology 2011;179:1148–56.CrossRefGoogle ScholarPubMed
Alcain, FJ, Villalba, JM. Sirtuin inhibitors. Expert Opinion on Therapeutic Patents 2009;19:283–94.CrossRef
Grozinger, CM, Chao, ED, Blackwell, HE, Moazed, D, Schreiber, SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. Journal of Biological Chemistry 2001;276:38 837–43.CrossRefGoogle ScholarPubMed
Napper, AD, Hixon, J, McDonagh, T, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. Journal of Medicinal Chemistry 2005;48:8045–54.CrossRefGoogle ScholarPubMed
Olmos, Y, Brosens, JJ, Lam, EW. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resistance Update 2011;14:35–44.CrossRef
Kwok, JM, Myatt, SS, Marson, CM, et al. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Molecular Cancer Therapeutics 2008;7:2022–32.CrossRef

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×